Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

11/15/2013 | 09:34pm US/Eastern

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
React to this article
Latest news
Date Title
02:53p RENTRAK : Announces Official Worldwide Box Office Results for Weekend of April 19, 2015
02:46p Investing in the Arts in Gananoque
02:38p HONEYWELL : Federal Contracts Awarded by Federal Agencies in Alabama (April 19)
02:38p LOCKHEED MARTIN : Federal Contracts Awarded to Companies in Maryland (April 19)
02:38p VIASAT : Federal Contracts Awarded by Federal Agencies in Pennsylvania (April 19)
02:38p LEIDOS : Federal Contracts Awarded by Federal Agencies in Missouri (April 19)
02:38p PARKER HANNIFIN : Federal Contracts Awarded by Federal Agencies in Oklahoma (April 19)
02:36p AUDI : reveals prologue allroad
02:36p MANCHESTER UNITED : Manuel Pellegrini hails vital Manchester City victory against West Ham
02:34p PHILLIPS 66 : gymnasts make mark at state meet
Latest news
Advertisement
Hot News 
OPPORTUNITY INVEST MGMT : 16 April 2015 - Update didivend payment
BEOWULF MINING : TR-1: Notification of Major Interest in Shares
TROVAGENE : Nasdaq stocks posting largest percentage increases
INSPIRIT ENERGY : Issue of Equity and Directors' Dealings 02 April 2015
GAMEACCOUNT NETWORK : DIRECTOR DEALINGS: GameAccount Non-Executive Buys 100,000 Shares
Most Read News
04/18 BANK OF MONTREAL : BMO Capital Markets and Variety Village : Unveil Playground for Children of All Abilities
08:47a DONGFENG MOTOR : PSA Peugeot Citroen and Dongfeng to develop small-car platform
05:13aDJDEUTSCHE BANK : Correction to Deutsche Bank Story
04/18 Conservatives aim to sell Lloyds shares to small investors
12:58p Shanghai GM to spend $16 billion developing new vehicles
Most recommended articles
02:21p Five years after BP oil spill, some Gulf oystermen are losing hope
02:13p PROLOGIS : to buy KTR Capital for $5.9 billion - WSJ
01:56pDJPrologis to Buy KTR for $5.9 Billion -- Update
01:33p BOJ's Kuroda says Japan inflation to 'gradually accelerate' toward target
12:58p Shanghai GM to spend $16 billion developing new vehicles
Dynamic quotes  
ON
| OFF